Navigation Links
NDC Completes Acquisition of Phase One Medical(R) Anchoring Technology
Date:3/2/2009

FREMONT, Calif., March 2 /PRNewswire/ -- Nitinol Devices & Components, Inc. (NDC) announced today that they recently acquired a novel medical device anchoring technology from Phase One Medical, LLC, brokered by Hatch Medical, LLC. This anchoring technology integrates the superelastic material properties of nitinol with proprietary anchoring design elements to provide secure fixation and removability for minimally invasive medical devices. The technology is anticipated to provide a platform for the production of a spectrum of innovative medical device therapies to the cardiovascular surgery and interventional radiology community.

Traditional anchoring technologies include, for example, barbs or hooks in vena cava filters, radial outward forces in endovascular stents, and pinching in atrial septal defect closure devices. Each of these technologies requires significant interaction with the surrounding anatomy such that the native biomechanics are disturbed, at times resulting in negative clinical outcomes. Many of these implantable devices are needed only for a short duration to assist in the natural healing process, after which time the device is no longer necessary and the body could benefit from removal of the device if the biological risks associated with removal are minimal.

The anchoring technology acquired from Phase One Medical offers several key advantages over those conventional technologies while retaining the same small dimensions required to deliver devices using minimally invasive techniques. First, this technology decouples device delivery and anchoring into two separate steps, allowing physicians the opportunity to fully unsheath devices in vivo, position them as necessary, and anchor the devices only after precise placement has been achieved. Second, the anchors may be retracted during the initial implantation procedure even after attachment to the anatomy, thereby providing physicians with mu
'/>"/>

SOURCE Nitinol Devices & Components, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Eligard(R) six-month formulation successfully completes European approval procedure
2. The ScottCare Corporation Completes Acquisition of Rozinn Electronics, a Leading Manufacturer of Cardiac Diagnostic Products
3. EaglePicher Corporation Completes Transaction to Sell EaglePicher Boron, LLC to Ceradyne, Inc. for $69 Million
4. Symmetry Medical Completes Acquisition Of Specialty Surgical Instruments
5. GSI Securitization Completes Merger and Domicile Transfer
6. Medical Services International Inc. Completes Testing for European Union (EU) Application
7. Inverness Completes Acquisition of Cholestech
8. Billians HealthDATA Completes Comprehensive Long Term Care Database Update
9. Synova Completes Sale of $3.3 Million in Senior Convertible Notes and Warrants
10. Explorer completes the map ... for the bodys blueprint
11. Labopharm completes enrolment for Phase III clinical study for its once-daily trazodone antidepressant drug

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2009)... No more letters from the North Po...lized text messages from Santa , ...increase operational efficiencies at the North Pol... keep children all over the globe informed of his ... Santa’s research department have identified...
(Date:11/25/2009)...DINA,Minn.,Nov.25/PRNewswire-USNewswire/--Whenmost...tachiropractorcanalsogivepatientsthehelptheyneed.T...eyourjaw(mandible)contacts/connectswithyourskull(t...dwithTMJdysfunctionarepainwithchewing,clickingorpo...MJdysfunctionincluding:headaches,fatigue,sleepdist...
(Date:11/25/2009)...ONGBEACH,Calif.,Nov.25/PRNewswire/--Thanksgivingme...iorsinthegreaterLongBeachareathankstoFaithInAction...denceatHome(IAH),adivisionofSCANHealthPlan.Formore...fvolunteerstodeliverwarmThanksgivingmealstoseniors...thLosAngelesandsurroundingcities. ,, "Ourwarmho...
(Date:11/25/2009)...rm survivors of testicular cancer who were treated... side effects, including neurological side effects... treated with chemotherapy, according to a new stu... the National Cancer Institute . , Marianne Bryd...University Hospital, in Bergen, Norway, and collea...
(Date:11/25/2009)..., already used to fight rheumatoid arthritis, coul... , WEDNESDAY, Nov. 25 (HealthDay News) -- A...a and rheumatoid arthritis now also shows some pro... 1 diabetes. , The drug, rituximab (Rituxan), h...sulin, even though the disease had destroyed some ...
Breaking Medicine News(10 mins):Health News:Text Messages from Santa | Santa goes GREEN by going MOBILE for The March of Dimes 2Health News:SCAN Employees and Community Volunteers to Help Deliver One Thousand Thanksgiving Meals to Homebound Seniors 2Health News:Type 1 Diabetes May Have a New Foe 2Health News:Type 1 Diabetes May Have a New Foe 3
...egory Laslo will travel to Washington, D.C., Sunda...t with congressional leaders and gain their suppor...earch toward a cure for epilepsy. , , Rundlett, 1...th support from Abbott. The program rallies young ...
... Phoenix, AZ, will travel to Washington, D.C., Su...meet with congressional leaders and gain their sup...research toward a cure for epilepsy. , , McArthur...nd funded by Abbott Laboratories. The program rall...
...use from intimate partners spent 42 percent more o...rding to a long-term study of more than 3,000 wome... The study revealed that women who suffered physic...cal and emotional pain it causes, domestic violenc...
...ces, Inc. announced today that it has provided $19...spital in Mountain View, California. The five-year...y of Siemens Medical Solutions equipment which wil...e than 40 years, El Camino Hospital has been servi...
...ty, IA will travel to Washington, D.C., Sunday, Ma...h congressional leaders and gain their support for... toward a cure for epilepsy. , , Carlson, 16, is ... by Abbott Laboratories. The program rallies young...
...Inc., the premier cancer diagnostics company and t...ay announced the appointment of Grady Barnes, Ph.D...o Fujirebio Diagnostics with 25 years of diagnosti...dian Bioscience. , , As Chief Scientific Officer,...
Other Medicine News:Health News:Maryland Youths Share Epilepsy Message on Capitol Hill 2Health News:Arizona Youth Shares Epilepsy Message on Capitol Hill 2Health News:Physical abuse raises women's health costs over 40 percent 2Health News:Siemens Financial Services, Inc. Announces Completion of Tax-Exempt Financing With El Camino Hospital 2Health News:Siemens Financial Services, Inc. Announces Completion of Tax-Exempt Financing With El Camino Hospital 3Health News:Iowa Youth Shares Epilepsy Message on Capitol Hill 2Health News:Fujirebio Diagnostics Appoints Grady Barnes as Chief Scientific Officer 2
(Date:11/25/2009)...inker.comannouncesthatanewmarketresearchreportisav...t-AGlobalMarketPerspective ,, http://www.rep...lobal-Market-Perspective.html ,, Risinginciden...nationsisaprincipalfactorinfluencinggrowthinthemam...eastcancerhasallowedwomentocomeforwardfortheiryear...
(Date:11/25/2009)...e/--SwissrayInternational,Inc.aleadingmanufacturer...todaythatitsoperationshavebeenacquiredbyaprivateSw...,smedicalimagingbrand.Theacquisitionincludedallass...entory.After25yearsofsuccessandgrowthSwissrayisnow...ntswithstableandsteadygrowth. ,, "Swissrayhaslo...
(Date:11/25/2009)...l/--NuVasive,Inc.(Nasdaq: NUVA ),amedicaldevicecom...ivesurgicaltreatmentsforthespine,announcedtodaytha...,at5:30p.m.ET/2:30p.m.PT.Theconferencecallwillfocu...ny,sproductsandwillincludecommentsfrommanagementfo...umbersare1-877-407-4018fordomesticcallersand1-201-...
Breaking Medicine Technology:Reportlinker Adds Mammography Equipment - A Global Market Perspective 2Reportlinker Adds Mammography Equipment - A Global Market Perspective 3Reportlinker Adds Mammography Equipment - A Global Market Perspective 4Reportlinker Adds Mammography Equipment - A Global Market Perspective 5Reportlinker Adds Mammography Equipment - A Global Market Perspective 6Reportlinker Adds Mammography Equipment - A Global Market Perspective 7Swissray International Announces New Ownership 2NuVasive Announces Conference Call and Webcast Regarding Reimbursement 2NuVasive Announces Conference Call and Webcast Regarding Reimbursement 3OPAXIO Produces High Rates of Pathologic Complete Remission in Patients with Advanced Esophageal Cancer 3B Study Paves Way for Potential Registration 5118 1OPAXIO Produces High Rates of Pathologic Complete Remission in Patients with Advanced Esophageal Cancer 3B Study Paves Way for Potential Registration 5118 2OPAXIO Produces High Rates of Pathologic Complete Remission in Patients with Advanced Esophageal Cancer 3B Study Paves Way for Potential Registration 5118 3OPAXIO Produces High Rates of Pathologic Complete Remission in Patients with Advanced Esophageal Cancer 3B Study Paves Way for Potential Registration 5118 4OPAXIO Produces High Rates of Pathologic Complete Remission in Patients with Advanced Esophageal Cancer 3B Study Paves Way for Potential Registration 5118 5LA BioMed study finds higher survival rate among intoxicated trauma patients 58613 1Algae and pollen grains provide evidence of remarkably warm period in Antarcticas history 10205 1Algae and pollen grains provide evidence of remarkably warm period in Antarcticas history 10205 2Algae and pollen grains provide evidence of remarkably warm period in Antarcticas history 10205 3Algae and pollen grains provide evidence of remarkably warm period in Antarcticas history 10205 4
...teria to Help Facilitate EHR Adoption in Small, Am..., March 3 The Certification Commission for Heal...rally recognized body for testing and certifying e...will develop dermatology-specific functionality cr... in part a response to an application from the Ame...
...IS, March 3 Novexel, a speciality pharmaceutical,...f novel antibiotics,designed to overcome the signi...unces today that its most advanced injectable anti... beta lactamase inhibitor, NXL104, with the,well e...has entered a second,Phase II clinical trial. , ...
Other Medicine Technology:Certification Commission for Healthcare Information Technology to Develop Dermatology-Specific Functionality Criteria for Electronic Health Record (EHR) Technology 2Novexel's NXL104/ceftazidime Combination Commences Second Phase II Clinical Trial in Hospital Patients With Complicated Intra-Abdominal Infections (cIAIs) 2Novexel's NXL104/ceftazidime Combination Commences Second Phase II Clinical Trial in Hospital Patients With Complicated Intra-Abdominal Infections (cIAIs) 3Novexel's NXL104/ceftazidime Combination Commences Second Phase II Clinical Trial in Hospital Patients With Complicated Intra-Abdominal Infections (cIAIs) 4
USA Series MICRO-6L Semi-Rigid Ureteroscope
...he ACMI DUR-8 Elite's 8.7 Fr shaft reaches into th...iding complete intrarenal access, even reaching th... covering and working channel ease insertion of bo...stable shaft construction, tight-bend radius tip, ...
...he ACMI USA Series DUR-8 Durable Flexible Ureteros...e entire intrarenal collecting system with little ... secondary deflection allow complete intrarenal ac...ction facilitates access to the proximal ureter an...
S-Series Cystourethroscope Standard Obturator
Medicine Products: